Assuntos
Acrodermatite/tratamento farmacológico , Fármacos Dermatológicos/uso terapêutico , Dedos , Dedos do Pé , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Ustekinumab/uso terapêutico , Idoso , Fármacos Dermatológicos/efeitos adversos , Esquema de Medicação , Seguimentos , Humanos , Injeções Subcutâneas , Masculino , Retratamento , Falha de TratamentoRESUMO
Psoriatic patients have a higher prevalence of diabetes mellitus type 2 (DM). Since dipeptidyl peptidase IV (DPP-IV) dysregulation is present in DM and psoriasis, DPP-IV inhibitors have been proposed as therapeutic agents for both conditions. We report a psoriasiform eruption induced by sitagliptin, a DPP-IV inhibitor. The role of DPP-IV in the pathogenesis of DM is well established; however data on psoriatic patients is contradictory. More studies are required to elucidate the effect of DPP-IV inhibitors and their relationship with DM and psoriasis.
Assuntos
Inibidores da Dipeptidil Peptidase IV/efeitos adversos , Toxidermias/etiologia , Psoríase/induzido quimicamente , Pirazinas/efeitos adversos , Triazóis/efeitos adversos , Diabetes Mellitus Tipo 2/epidemiologia , Extremidades , Feminino , Humanos , Pessoa de Meia-Idade , Psoríase/epidemiologia , Fosfato de Sitagliptina , TroncoAssuntos
Adenocarcinoma/cirurgia , Neoplasias Pulmonares/cirurgia , Complicações Pós-Operatórias/diagnóstico , Pioderma Gangrenoso/diagnóstico , Toracotomia/efeitos adversos , Anti-Inflamatórios/uso terapêutico , Biópsia , Diagnóstico Diferencial , Feminino , Humanos , Pessoa de Meia-Idade , Complicações Pós-Operatórias/tratamento farmacológico , Complicações Pós-Operatórias/patologia , Prednisona/uso terapêutico , Pioderma Gangrenoso/tratamento farmacológico , Pioderma Gangrenoso/patologia , Pele/patologiaRESUMO
Cetuximab, an epidermal growth factor receptor inhibitor, is a chemotherapeutical agent featuring well-known adverse dermatological effects related to tumour-response prognosis. In psoriasis, the epidermal growth factor receptor is overexpressed; hence, the expectation would be that an epidermal growth factor receptor inhibitor could improve psoriatic lesions. We report a case of psoriasis induced by cetuximab, which was a surprising adverse effect.
Assuntos
Anticorpos Monoclonais/efeitos adversos , Antineoplásicos/efeitos adversos , Psoríase/induzido quimicamente , Anticorpos Monoclonais Humanizados , Cetuximab , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
Nitric oxide (NO) is a potent regulator of keratinocyte growth and differentiation that has been implicated in the pathogenesis of psoriasis (Ps). The NOS3 -786 T/C (SNP id rs2070744; http://www.ensembl.org ), intron 4 variable number tandem repeat (VNTR), and Glu298Asp (SNP id rs1799983) polymorphisms, have been associated with differences in NO plasma concentrations and with the risk of hypertension (HT) and ischemic cardiac disease. The aim of this study was to determine whether the above-mentioned NOS3 variants contributed to the risk of Ps, and were associated with the risk for HT and CAD in these patients. A total of 368 patients with chronic plaque Ps and 400 healthy controls were genotyped for the NOS3 -786 T/C, intron 4 VNTR, and Glu298Asp polymorphisms. Carriers of the -786 C allele were significantly more frequent among the patients (p < 0.001). Carriers of the 4-repeats allele (45 + 44 genotypes) were also more frequent a (p < 0.001). No significant difference was found for the Glu298Asp polymorphism. None of the NOS3 variants was associated with Ht and CAD in our population. In conclusion, NOS3 gene polymorphism would be risk factors for developing Ps.
